IP Library › Granted Patent US 10,442,828
Granted Patent B2
US 10,442,828 · App. 16/021,519 · Granted Oct 15, 2019

Kinase inhibitors

Inventors: Matthew Colin Thor Fyfe (London, GB); Stephen Malcolm Thom (Nottingham, GB)
Assignee: Topivert Pharma Limited
C07F9/58A61K31/44A61K31/443A61K31/4412A61K31/4436A61K31/4439A61K31/501A61K31/505A61K31/506A61K31/675A61K45/06C07D213/73C07D213/74C07D239/47C07D401/12C07D403/12C07D405/12C07D409/12C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,442,828
App. No.
16/021,519
Granted
Oct 15, 2019
Kind
B2
Abstract

There are provided compounds of: wherein T, A, Q, Z, R 4 , R 5a , R 5b , n, r, Het 1 and R x have meanings given in the description, which compounds are useful in synthesizing compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Claims (81)

1. A compound of formula I(P):

or a salt thereof,

wherein:

wherein R x represents C 1-6 alkyl or benzyl;

T represents

W represents O, S or NCH 3 ;

V represents N or CR 1 ;

R 1 represents C 1-3 alkoxy, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, which latter four groups are optionally substituted by one or more substituents selected from halo, hydroxy and C 1-2 alkoxy, or R 1 represents H;

R 2 represents —NR A1 S(O) 2 R B1 , —S(O) 1-2 R B2 , —P(O)R B3 R B4 , —C(O)NR A2 R A3 or —CH 2 NR A4 C(O)R A5 ;

R A1 to R A5 independently represent H or C 1-3 alkyl optionally substituted by one or more substituents selected from halo, hydroxy, NR C R D and C 1-2 alkoxy, or R A2 and R A3 together represent C 3-6 n-alkylene or C 4-5 n-alkylene interrupted between C2 and C3 by —O—, —S(O) q — or —N(R E )—;

R B1 to R B4 independently represent C 1-3 alkyl or C 3-6 cycloalkyl, which latter two groups are optionally substituted by one or more halo substituents;

R C and R D independently represent H or C 1-3 alkyl, which latter substituent is optionally substituted by hydroxyl or C 1-2 alkoxy, or R C and R D together combine to form C 4-6 alkylene optionally interrupted between C2 and C3 by —O—, —S(O) q — or —N(R E )—;

R E represents H or methyl;

q represents 0, 1 or 2;

R 3 represents C 2-7 alkyl, C 2-7 alkenyl, C 2-7 alkynyl or C 3-7 cycloalkyl, which latter four groups are optionally substituted by hydroxyl, C 1-2 alkoxy or halo, or R 3 represents morpholinyl or trimethylsilyl;

A represents CH or N;

R 4 represents C 1-3 alkoxy, C 3-5 cycloalkoxy, or C 1-3 alkyl, which latter three groups are optionally substituted by one or more halo substituents, or R 4 represents ethynyl, cyano, S(O) 2 CH 3 , halo or H;

Q represents O, S(O) p , SO 2 N(R 6 ) or C(O)N(R 6 );

n represents 1, 2 or 3;

p represents 0, 1 or 2;

R 5a and R 5b independently represent H, methyl or halo, or R 5a and R 5b together represent C 2-6 n-alkylene;

when n represents 1, Z represents O, S or NR 7 or,

when n represents 2 or 3, Z represents either

an O-atom on each occurrence, or

either an S-atom or NR 7 on one occurrence and an O-atom on each other occurrence;

R 6 and R 7 independently represent H or methyl;

r represents 0 or, when Het 1 is attached to (CH 2 ) r via a ring heteroatom, r may alternatively represent 1; and

Het 1 represents

a 5- or 6-membered heterocyclic group that is fully aromatic, which group contains one or more heteroatoms selected from N, O and S or

a 4- to 7-membered heterocyclic group that is fully saturated or partially unsaturated, and is monocyclic or is fused or bridged bicyclic, which group contains one or more heteroatoms selected from N, O and S,

wherein Het 1 is optionally substituted by one or more substituents selected from C 1-3 alkyl, C 1-3 alkoxy, halo, hydroxyl and oxo.

2. A compound of formula I(P) as claimed in claim 1 , wherein:

R 1 represents methoxy;

R 2 represents —NHS(O) 2 CH 3 ;

R 3 represents tert-butyl;

A represents CH;

R 4 represents methoxy;

R 5a and R 5b both represent H;

Q represents O;

Z represents O;

n represents 2; and/or

R x represents ethyl.

3. A compound as claimed in claim 1 which compound is:

(ethyl 2-(2-(2-(3-((4-((4-(3-(5-(tert-butyl)-2-methoxy-3-(methylsulfonamido)phenyl)ureido)-naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxyphenoxy)ethoxy)ethoxy)acetate), or a salt thereof.

4. A compound:

(a) of formula II or IIb:

or a salt or protected derivative thereof,

wherein

LG 1 represents a leaving group; and

Z 1 is a structural fragment of formula V:

wherein G represents —[(CH 2 ) r -Het 1 ] 0-1 —C(O) 2 H or a carboxylic acid isostere and R 4 , R 5a , R 5b , A, Q, Z, n and Het 1 are as defined in claim 1 and;

wherein the protected derivative of the compound of formula II or IIb is a compound in which, when G represents —[(CH 2 ) r -Het 1 ] 0-1 —C(O) 2 H, the C(O) 2 H moiety is protected as an ester of formula C(O)OR x , wherein R x represents C 1-6 alkyl or benzyl; or

(b) of formula III,

or a salt or protected derivative thereof, wherein Z 2 is a structural fragment of formula V, as defined above,

wherein the protected derivative of the compound of formula III is a compound

(i) in which the NH 2 group of formula III is replaced by nitro, or in which a H-atom of the NH 2 group of formula III is replaced by

R′—C(O)—, wherein R′ is C 1-8 alkyl optionally substituted by one or more fluoro groups or R′ is H, phenyl or benzyl, which latter two groups are optionally substituted by one or more groups selected from halo, hydroxy, methyl and methoxy; or

R″—O—C(O)—, wherein R″ is tert-butyl, phenyl, benzyl or fluorenyl, which latter three groups are optionally substituted by one or more groups selected from halo, hydroxy, methyl and methoxy; and/or

(ii) in which, when G represents —[(CH 2 ) r -Het 1 ] 0-1 —C(O) 2 H, the C(O) 2 H moiety of formula III is protected as an ester of formula C(O)OR x , wherein R x represents C 1-6 alkyl or benzyl.

5. A compound of formula II, IIb or III as claimed in claim 4 , or a salt or protected derivative thereof, wherein:

A represents CH;

R 4 represents methoxy;

R 5a and R 5b both represent H;

Q represents O;

Z represents O; and/or

n represents 2.

6. A compound of formula III, or a salt thereof, as claimed in claim 4 , which compound is

(ethyl 2-(2-(2-(3-((4-((4-((tert-butoxycarbonyl)amino)naphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxyphenoxy)ethoxy)ethoxy)acetate) or

(ethyl 2-(2-(2-(3-((4-((4-aminonaphthalen-1-yl)oxy)pyridin-2-yl)amino)-5-methoxyphenoxy)ethoxy)ethoxy)acetate).

7. A compound of formula IIb, or a salt or protected derivative thereof, as claimed in claim 4 , wherein LG 1 represents imidazolyl, chloro, or aryloxy.

8. A compound of formula IIb, or a salt or protected derivative thereof, as claimed in claim 4 , wherein:

LG 1 represents phenoxy; and

G represents C(O) 2 H,

wherein the protected derivative of the compound of formula IIb is a compound in which the C(O) 2 H moiety is protected as an ester of formula C(O)OR x , wherein R x represents C 1-6 alkyl or benzyl.

9. A compound of formula IIb, or a salt or protected derivative thereof, as claimed in claim 8 , wherein

A represents CH;

R 4 represents methoxy;

R 5a and R 5b both represent H;

Q represents O;

Z represents O; and/or

n represents 2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: TOPIVERT PHARMA LIMITED
To: OXULAR ACQUISITIONS LIMITED
Reel/Frame 054610/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: RESPIVERT LIMITED
To: TOPIVERT PHARMA LIMITED
Reel/Frame 047725/0470 →
Priority Claims (1)
GB 1605844.8 · Apr 6, 2016 · national
Continuity (2)
Division 15480689 · Apr 6, 2017
Related Publication 20180305383A1 · Oct 25, 2018